Fri, May 27, 2011
Thu, May 26, 2011
Wed, May 25, 2011
Tue, May 24, 2011
Mon, May 23, 2011
Sun, May 22, 2011
Fri, May 20, 2011
Thu, May 19, 2011
Wed, May 18, 2011
Tue, May 17, 2011
Mon, May 16, 2011
Sun, May 15, 2011
[ Sun, May 15th 2011 ] - Market Wire
Teva to Acquire Taiyo
Fri, May 13, 2011
Thu, May 12, 2011
Wed, May 11, 2011
Tue, May 10, 2011
Mon, May 9, 2011
Sun, May 8, 2011
Sat, May 7, 2011
Fri, May 6, 2011
Thu, May 5, 2011
Wed, May 4, 2011
Tue, May 3, 2011
Mon, May 2, 2011
Fri, April 29, 2011
Thu, April 28, 2011

SuperGen to Present at BioEquity Europe on May 23rd & 24th


//health-fitness.news-articles.net/content/2011/ .. resent-at-bioequity-europe-on-may-23rd-24th.html
Published in Health and Fitness on Monday, May 16th 2011 at 5:05 GMT by Market Wire   Print publication without navigation


DUBLIN, Calif.--([ BUSINESS WIRE ])--SuperGen, Inc. (NASDAQ:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that James S.J. Manuso, Ph.D., president and chief executive officer, will present at BioEquity Europe 2011 on Monday and Tuesday, May 23rd and 24th in Paris.

SuperGen's corporate presentation will take place on May 23 at 11:00 a.m. CEST. In addition, Dr. Manuso will participate in a panel discussion titled, aStrategy: Squaring the Circlea about building companies to study disease biology based on platform technology, on May 24 at 1:45 p.m. CEST. More information on the panel can be found at [ http://www.biocentury.com/Conferences ].

About SuperGen

SuperGen is a pharmaceutical company dedicated to discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization. On April 6, 2011, SuperGen entered into a definitive merger agreement to acquire Astex Therapeutics Limited, a UK based biotechnology company. The transaction is subject to customary regulatory, legal and shareholder approvals. For more information about SuperGen, please visit [ http://www.supergen.com ].


Publication Contributing Sources